Core Laboratories director awarded 7,895 restricted shares

Core Laboratories director Katherine Murray reported equity compensation activity.

Accepted by SEC EDGAR 04/08/2026 - 12:22 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Core Laboratories director Katherine Murray reported equity compensation activity. She received a grant of 7,895 Restricted Shares that will vest after a one-year period ending on April 1, 2027, subject to issuance terms and an elective deferral. Separately, 8,069 Restricted Shares completed a prior one-year vesting period and converted into 8,069 shares of Common Stock at no cost, bringing her directly held Common Stock to 29,290 shares.

Insider Trade Summary

8,069 shares exercised/converted

Exercise 3 txns

Insider Murray Katherine

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Shares	7,895	$0.00	$0.00
Exercise	Restricted Shares	8,069	$0.00	$0.00
Exercise	Common Stock	8,069	$0.00	$0.00

Holdings After Transaction: Restricted Shares — 7,895 contracts (Direct); Common Stock — 29,290 shares (Direct)

Holdings Before and After: Restricted Shares, 8,069 to 7,895 contracts (Direct); Common Stock, 21,221 to 29,290 shares (Direct)

Footnotes (2)

1. F1. The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period on April 1, 2027, subject to the terms of issuance. Such shares remain subject to a deferral election by the Reporting Person in accordance with Treasury Regulation 1.409A-2, and the vested portion thereof will be distributed as shares of common stock following the Reporting Person's separation of service from the Board.
2. F2. The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2026.

Key Figures

Restricted Shares granted: 7,895 shares Restricted Shares vested: 8,069 shares Exercise/Conversion price: $0.00 per share +2 more

5 metrics

Restricted Shares granted 7,895 shares New grant vesting after one-year period ending April 1, 2027

Restricted Shares vested 8,069 shares Vested after one-year vesting period ending April 1, 2026

Exercise/Conversion price $0.00 per share Conversion of 8,069 Restricted Shares into Common Stock

Common Stock held after transactions 29,290 shares Directly held by Katherine Murray following the April 1, 2026 activity

New Restricted Shares underlying security 7,895 Common Stock shares Underlying security for newly granted Restricted Shares

Key Terms

Restricted Shares, vesting period, deferral election, Treasury Regulation 1.409A-2

4 terms

Restricted Shares financial

"The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period"

Restricted shares are company stock that cannot be sold or transferred immediately because they are subject to legal or contractual limits, such as a required holding period or performance conditions. They matter to investors because these locked-up shares can affect a company’s available stock for trading, future dilution, and insider incentives—imagine a gift that can’t be cashed until certain conditions are met, which changes when and how much supply can suddenly enter the market.

vesting period financial

"The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period"

A vesting period is the set amount of time someone must wait before they fully own granted shares, stock options, or other equity tied to their work or an agreement; ownership increases gradually or in steps during that time. Investors care because vesting determines when insiders or employees can sell shares, which affects future supply of stock, company incentives and executive retention—think of it like unlocking ownership over installments rather than receiving it all at once.

deferral election financial

"Such shares remain subject to a deferral election by the Reporting Person in accordance with Treasury Regulation 1.409A-2"

Treasury Regulation 1.409A-2 regulatory

"Such shares remain subject to a deferral election by the Reporting Person in accordance with Treasury Regulation 1.409A-2"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Core Laboratories (CLB) director Katherine Murray report?

Katherine Murray reported routine equity compensation activity. She received 7,895 Restricted Shares and had 8,069 previously granted Restricted Shares vest and convert into Common Stock at no cost, increasing her directly held Common Stock position to 29,290 shares.

How many Core Laboratories (CLB) Restricted Shares were granted to Katherine Murray?

Katherine Murray was granted 7,895 Restricted Shares. These shares are scheduled to vest after a one-year vesting period ending April 1, 2027, subject to the terms of issuance and a deferral election that can delay distribution until after she leaves the Board.

Did Katherine Murray sell any Core Laboratories (CLB) shares in this Form 4 filing?

The filing shows no sales. All transactions are acquisitions: a grant of 7,895 Restricted Shares and the vesting and conversion of 8,069 Restricted Shares into Common Stock, with her directly held Common Stock rising to 29,290 shares following these transactions.

What happened to the 8,069 Restricted Shares reported by Katherine Murray at Core Laboratories (CLB)?

The 8,069 Restricted Shares completed a one-year vesting period ending April 1, 2026. They were exercised or converted at a price of $0.00 per share into 8,069 shares of Common Stock, contributing to Katherine Murray’s total directly held Common Stock position of 29,290 shares.

When will Katherine Murray’s new Core Laboratories (CLB) Restricted Shares vest and be distributed?

The 7,895 newly granted Restricted Shares will vest at the end of a one-year vesting period on April 1, 2027. Under a deferral election, vested shares will be distributed as Common Stock after Katherine Murray’s separation of service from the Core Laboratories Board.

How many Core Laboratories (CLB) Common Stock shares does Katherine Murray hold after these transactions?

After the reported transactions, Katherine Murray directly holds 29,290 shares of Core Laboratories Common Stock. This total reflects the conversion of 8,069 previously restricted shares into Common Stock, in addition to her existing holdings prior to this Form 4 filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Murray Katherine

(Last) (First) (Middle)

6316 WINDFERN ROAD

(Street)

HOUSTON TEXAS 77040

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Core Laboratories Inc. /DE/ [ CLB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/01/2026		M		8,069	A	$0	29,290	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Shares	$0	04/01/2026		A		7,895		(1)	(1)	Common Stock	7,895	$0	7,895	D
Restricted Shares	$0	04/01/2026		M			8,069	(2)	(2)	Common Stock	8,069	$0	0	D

Explanation of Responses:

1. The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period on April 1, 2027, subject to the terms of issuance. Such shares remain subject to a deferral election by the Reporting Person in accordance with Treasury Regulation 1.409A-2, and the vested portion thereof will be distributed as shares of common stock following the Reporting Person's separation of service from the Board.

2. The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2026.

	/s/ Mark Tattoli, Attorney-in-Fact	04/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)